DESCRIPTIVE EPIDEMIOLOGY OF TB IN BC AND CANADA
Jordan AE, Nsengiyumva NP, Houen RM, et al. The prevalence of tuberculosis infection among foreign-born Canadians: A modelling study. CMAJ 2024 195(48):E1651-1659.
Campbell JR, Nsengiyumva, Chiang L, et al. Costs of tuberculosis at three Canadian centres: a retrospective study. Emerging Infectious Diseases 2022; 28(9):1814-1823.
Puyat JH, Shulha HP, Balshaw R, et al. Law S, Menzies R, Johnston JC. How well does TSTin3D predict risk of active tuberculosis in the Canadian immigrant population? An external validation study. Clin Inf Dis. 2021 73(9):e3486-3495.
Ronald LA, Campbell JR, Balshaw RF, et al. Demographic predictors of active tuberculosis in people migrating to British Columbia. Canada: a retrospective cohort study. CMAJ. 2018 February 26; 190(8): E209-E216
Romanowski K, Sobkowiak B, Guthrie JL, et al. Using whole-genome sequencing to determine the timing of secondary tuberculosis in British Columbia, Canada. Clinical Infectious Diseases. 2021. 73(3):535-537
POST-TB OUTCOMES
K Romanowski, VJ Cook, M Gilbert, JC Johnston. Using a theory-informed approach to guide the initial development of a post-tuberculosis care package in British Columbia, Canada. 2023; BMC Health Services Research 23 (1), 805
Romanowski K, Amin P, Johnston JC. Improving Post-Tuberculosis Care in Canada. Canadian Medical Association Journal 2023; 195(5): e217-e219.
Romanowski K, Law MR, Karim ME, et al. Healthcare utilization after respiratory tuberculosis: a controlled interrupted time series analysis. Clinical Infectious Diseases. 2023 77(6):883-891.
Romanowski K, Baumann B, Basham CA, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2019; 19(10): 1129-1137.
Basham CA, Romanowski K, Johnston, JC. Life after tuberculosis: planning for health. The Lancet Respiratory Medicine. 2019 October 29; 7(12):1004-1006.
Basham CA, Karim ME, Cook VJ, et al. Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985–2015: a time-dependent cox regression analysis of linked immigration, public health, and vital statistics data. Canadian Journal of Public Health. 2020 Jul 14; 112(1): 132-141.
Basham CA, Karim ME, Cook VJ, et al. Post-tuberculosis airway disease: a population-based cohort study of people immigrating to British Columbia, Canada, 1985-2015 . E clinical Medicine. 2021 February 26; 33: 100752
Basham CA, Karim ME, Cook VJ, et al. Tuberculosis associated depression: a population –based cohort study of people immigrating to British Columbia, Canada, 1985-2015. Annals of Epidemiology 2021; 63:7-14.
RANDOMIZED CONTROLLED TRIALS
Ruslami R, Fregonese F, Apriani L, et al. High-dose, short-duration versus standard rifampicin for tuberculosis preventative treatment: a partially blinded, three-arm, non-inferiority, randomized, controlled trial. The Lancet Respiratory Medicine 2024.
Menzies D, Obeng J, Hadisoemarto P, et al. Sustainability and impact of an intervention to improve initiation of tuberculosis preventative treatment: results from a follow-up study of the ACT4 randomized trial. EclinicalMedicine. 2024(71)
Oxlade O, Benedetti A, Adjobimey M, et al. Effectiveness and cost-effectiveness of a health systems intervention for late tuberculosis infection management: a cluster randomized trial. Lancet Pub Health. 2021 6(5):e272-282.
Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. NEJM 2018; 379:440-453.
Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in Children. NEJM 2018; 379:454-463.
Johnston JC, Van Der Kop ML, Smillie K, et al. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. Eur Resp J. 2018 February 7; 51(2): 1701488.